{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"For the phase 1b portion of the trial, a dose-limiting toxicity (DLT) was defined as an adverse event at least possibly related to the study medication:\n\nNon-hematologic DLT is defined as any Grade 3 or greater ADR (adverse drug reaction), except symptomatic AEs such as nausea, vomiting, and diarrhea which could be reduced to less than Grade 3 within 72 hours with standard supportive measures (i.e., antiemetics and antidiarrheals).\n\nHematologic DLT is defined as\n\n* Grade 4 neutropenia or thrombocytopenia that lasts more than 7 days after the last dose of study drug\n* or greater than or equal to Grade 3 thrombocytopenia in the presence of greater than or equal to Grade 3 hemorrhage of any organ/site\n* or any Grade 5 hematologic toxicity","groups":[{"description":"ABC294640 250 mg BID given continuously","id":"OG000","title":"ABC294640 250 mg BID"},{"description":"ABC294640 250 mg BID given continuously","id":"OG001","title":"ABC294640 500 mg BID"},{"description":"ABC294640 750 mg BID given continuously","id":"OG002","title":"ABC294640 750 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants receiving any amount of study drug","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Patients With Dose Limiting Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}